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Extracorporeal removal techniques such as hemodialysis,
charcoal hemoperfusion, and peritoneal dialysis have been
used to remove toxins from the body. To define trends in the
use of these techniques for toxin removal, we analyzed the
19,351 cases requiring extracorporeal removal reported to
U.S. poison centers from 1985–2005. The number of such
patients who received hemodialysis, excluding those with
other medical indications, (normalized per million calls)
increased from 231 to 707 whereas hemoperfusion
decreased from 53 to 12 in the years 1985–2005. Peritoneal
dialysis decreased from 2.2 in 1985 to 1.6 in 1991. The most
common toxins removed by hemodialysis were lithium and
ethylene glycol. There were more dialysis treatments for
poisonings with valproate and acetaminophen in 2001–2005
than for methanol and theophylline, although hemodialysis
for acetaminophen removal is generally not recommended.
Theophylline was the most common toxin removed by
hemoperfusion from 1985–2000, but carbamazepine became
the most frequent toxin for removal during 2001–2005. Our
study shows that the profile of toxins and the type of
extracorporeal technique used to remove the toxins have
changed over the years.
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Extracorporeal removal techniques such as hemodialysis
(HD) and charcoal hemoperfusion (HP), and less so
peritoneal dialysis (PD), effectively increase the clearance of
certain toxins. Historically, these techniques have been
recommended as treatment for a serious overdose from a
select number of toxins, including salicylates, lithium,
ethylene glycol, methanol, and theophylline.1 Extracorporeal
removal has also been used for cases of serious poisoning
from a variety of other toxins, such as methotrexate, valproic
acid, and phenobarbital.2–4 In recent years the indications for
extracorporeal removal have changed as new drugs have been
introduced and others have become obsolete. Improvements
in supportive care, changes in gastrointestinal decontamina-
tion philosophies,5,6 and the introduction of relevant
antidotes, such as fomepizole, also influence the indications
for extracorporeal removal of toxins. Unfortunately, the
current epidemiology of the use of extracorporeal removal
techniques for poisoning is largely unknown.
The American Association of Poison Control Centers
developed the National Data Collection System in 1983 as a
database to gather and catalogue exposures reported to
participating poison centers. Ten years later, in 1993, this
system was revamped with fields that allowed collection of
more detailed information on each reported exposure, and it
was renamed the Toxic Exposure Surveillance System (TESS).
In 2007 it became the National Poison Data System.
The TESS database possesses information on each
reported exposure under the following major fields: Demo-
graphics of Exposure, Route of Exposure, Clinical Effects,
Therapeutics, and Outcomes. Each major field has many
minor fields allowing detailed information to be recorded,
usually in a check-box fashion. Specifically, the Therapeutics
field allows specialists in poison information to record both
the recommendation for and the actual occurrence of a
variety of therapeutic options including gastrointestinal
decontamination, antidote administration, cardiac and
respiratory support modalities, and extracorporeal removal
techniques.
Since its inception, the TESS database has been periodi-
cally modified to expand certain data fields, as well as to
delete others. In 1985, TESS could only record the names of
http://www.kidney-international.org o r i g i n a l a r t i c l e
& 2008 International Society of Nephrology
Received 21 March 2008; revised 10 June 2008; accepted 15 July 2008;
published online 17 September 2008
This paper was presented at the European Association of Poison Centers
and Clinical Toxicologists in Athens, Greece, in May 2007. The abstract was
published in Clin Toxicol 2007; 45: 346.
Correspondence: David S. Goldfarb, Nephrology Section, New York Harbor
VA Medical Center/111G, 423 East 23rd Street, New York, New York 10010,
USA. E-mail: David.Goldfarb@va.gov
Kidney International (2008) 74, 1327–1334 1327
up to two toxins for each case. Beginning in 1993, TESS could
record the total number of toxins involved for each case but
could only document the names of two toxins. Also, the field
for PD was removed and thus no longer recorded. Beginning
in 2000, TESS was able to record a limitless number of toxin
exposures with the names of each specific toxin for each case.
The American Association of Poison Control Centers
summarizes select portions of the data in a published annual
report. Through 1986, specific information about the
indications for extracorporeal removal was included in these
annual reports but not since.
The purpose of this study was to define trends in the use
of HD, HP, and PD as therapeutic modalities for toxic
exposures in the United States over a 21-year period of
poison center data recorded in the TESS database.
RESULTS
From 1985 to 2005 there were a total of 21,341 cases that had
HD, HP, and/or PD recommended and/or performed with
19,351 cases receiving extracorporeal removal. There were
13,995 one-toxin exposures, of which 12,706 received HD,
1261 received HP, and 28 received PD. There were 3577 two-
toxin exposures, of which 3531 received HD, 351 received HP,
and 6 received PD; 311 cases were exposed to two toxins
listed in Table 1. There were 1779 multi-toxin exposures, of
which 2027 received HD and 89 received HP (PD was no
longer recorded in TESS); 292 cases were exposed to two
toxins listed in Table 1, 18 cases exposed to three toxins, and
3 cases exposed to four toxins (Figure 1).
When normalized for the number of cases reported
annually (per million calls), the number of cases receiving
HD has steadily increased from 231 in 1985 to 707 in 2005.
The normalized number of cases receiving HP was 53 in
1985, sharply rose to a high of 132 in 1987, and then rapidly
decreased to below 29 by 1995 (Figure 2). The normalized
number of cases receiving PD was 2.2 in 1985, rising to a high
of 5.5 in 1986, and then decreasing to 1.6 by 1991 (Figure 3).
The most common toxins responsible for HD are shown
in Table 2. During this 21-year period, lithium and ethylene
glycol were the most common. Although salicylates, metha-
nol, and theophylline rounded out the top five from 1985 to
2000, from 2001 to 2005, valproic acid and acetaminophen
increased dramatically, surpassing methanol and theophyl-
line.
The most common toxins responsible for cases receiving
HP are shown in Table 3. Theophylline was the most
common toxin from 1985 to 2000, but then fell off from 2001
to 2005. Carbamazepine consistently remained high on the
list, becoming the most common toxin for HP from 2001 to
2005.
After excluding cases with non-toxin-related, medical
indications for extracorporeal treatment, the normalized
numbers of cases receiving HD and/or HP for aminophylline
and theophylline, antiepileptics (for example, carbamazepine,
phenytoin, valproic acid), ethylene glycol, lithium, methanol,
mushrooms, paraquat, salicylates, and sedative hypnotics (for
example, carisoprodol, chloral hydrate, ethchlorvynol, me-
probamate) were calculated. The trends for the most
commonly accepted indications (for example, theophylline,
ethylene glycol, lithium, methanol, and salicylates) are shown
graphically in Figure 4, whereas the results for the remaining
toxins are listed in Table 4.
The normalized number of theophylline cases per million
calls receiving HD was at a high of 28 in 1994 and decreased
to 4.5 in 2005. A similar trend was observed in normalized
number of cases receiving HP, with a high of 21.3 in 1994,
decreasing to 1.3 in 2003. There were no theophylline cases
reportedly receiving HP in 2004 or 2005. Interestingly, the
normalized number of ethylene glycol cases receiving HD
and/or HP has increased from 74.2 in 1993 to 171.2 in 2005,
whereas cases of methanol exposures experienced a less
dramatic increase from 25.1 in 1993 to 40.4 in 2005. The
normalized number of lithium cases receiving HD and/or HP
also increased from 81.1 in 1993 to 141.5 in 2005. The
normalized number of salicylate cases receiving HD and/or
HP experienced a large increase from 30.3 in 1993 to 89.1 in
2005.
For our post hoc analysis, there were a total of 248 cases
that had extracorporeal removal performed during the years
2000–2005: 243 received HD, 4 cases received HP, and 1
additional case as receiving both HD and HP. We excluded
108 cases with an exposure to a toxin not listed in Table 1. Of
the remaining 140 cases with an exposure to a toxin listed in
Table 1, 5 cases were thought to have received extracorporeal
removal for another non-toxin-related issue, meaning that 5
out of the 140 cases (3.6%) would be falsely included using
our inclusion criteria and assumptions. Further post hoc
analysis revealed 13 cases that would have been excluded for
having unrelated medical indications for HD. Of these 13
cases, 12 most likely received HD for toxin-related issues,
meaning that 12 out of the 140 cases (8.6%) were falsely
excluded.
DISCUSSION
We report the first comprehensive epidemiologic analysis of
TESS data regarding the use of extracorporeal removal
techniques. During the 21-year period of poison center data
collection there was an increase in reported use of HD and a
decrease in the reported use of HP. Several reasons may
account for these trends. First and foremost, because of the
improved efficacy of HD it may have replaced HP in many
cases. Currently, synthetic dialysis membranes (for example,
polysulfone) with greater dialysance are used more frequently
than older cellulose acetate or cuprophane membranes.7
Using theophylline as an example, these newer high-flux
membranes and advanced HD technologies have allowed HD
to obtain similar clearance rates when compared to the
classical HP technique. This is supported by a growing
number of new indications to use HD to remove molecules
with larger molecular weights including vancomycin, metho-
trexate, and phenobarbital.7 Computerized ultrafiltration
control and bicarbonate-based (rather than acetate-based)
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dialysate are other innovations during the study period that
have improved patient tolerance of HD. Along with improved
HD technique there has been a substantial decrease in the
availability of HP cartridges8 and some evidence suggesting
rapid saturation of HP cartridges resulting in a reduced
extraction ratio.9 As a result of these factors, it is reasonable
Table 1 | Toxins with generally accepted indications for extracorporeal removal in an overdose setting
Toxins TESS: major category TESS: minor category
Aminoglycosidesa Systemic Antibiotic: systemic (p.o., i.v., i.m.) preparation
Topical Antibiotic: topical (dermal, otic, ophthalmic, nasal) preparation
Unknown Antibiotic: unknown preparation
Aminophylline Aminophylline/theophylline Aminophylline/theophylline
Atenolola b-Blocker b-Blocker (include propanolol)
Carbamazepine Carbamazepine Carbamazepine
Carisoprodol Carisoprodol Aspirin with carisoprodol
Carisoprodol (formulated alone) Carisoprodol (formulated alone)
Chloral hydrate Chloral hydrate Chloral hydrate
Disopyramidea Antiarrhythmic: other Antiarrhythmic (quinidine, bretyllium, procainamide, etc.)
Ethchlorvynol Ethchlorvynol Ethchlorvynol
Ethylene glycol Ethylene glycol Automotive product
Ethylene glycol Excluding automotive/aircraft/boat product
Isopropanol Isopropanol Glass cleaner
Isopropanol Excluding rubbing alcohols and cleaning substance
Isopropanol Misc. cleaning agent
Isopropanol Wall/floor/tile/all-purpose cleaner
Isopropanol with methyl salicylate Rubbing alcohol
Isopropanol without methyl salicylate Rubbing alcohol
Lithium Lithium Lithium
Lithium Disc battery: lithium
Meprobamate Meprobamate Meprobamate
Methanol Methanol Automotive product
Methanol Excluding automotive product
Methanol Misc. cleaning agent
Methotrexatea Antineoplastic Antineoplastic drugs—miscellaneous
Mushroom Cyclopeptide Mushroom: cyclopeptide
Orellanine Mushroom: orellanine
Other potentially toxic Other potentially toxic mushroom
Unknown Unknown mushroom
Paraquat Paraquat Paraquat
Phenobarbitala Long acting Barbiturate: long acting
Short/intermediate acting Barbiturate: short and intermediate acting
Unknown type Barbiturate: unknown
Phenothiazine Phenothiazine Phenothiazine
Phenytoin Phenytoin Phenytoin
Salicylates Adult formulation Aspirin
Aspirin with other ingredient Aspirin with other ingredient
Aspirin without other ingredient Aspirin without other ingredient
Camphor/methyl salicylate Camphor and methyl salicylate
Codeine Aspirin with codeine
DXM APAP/ASA decon/antihist/without PPA/DXM
Methyl salicylate Methyl salicylate
Other drug: adult formulation Aspirin with other drug
Other opioid Aspirin with other opioid
Oxycodone Aspirin with oxycodone
Pediatric formulation Aspirin
Salicylate containing Antacid: salicylate containing
Unknown formulation Aspirin: unknown if adult or pediatric
With opioid ASA/decon/antihist/PPA/without opioid
With opioid ASA/decon/antihist/without PPA and opioid
Theophylline Aminophylline/theophylline Aminophylline/theophylline
Trichloroethanola Chlorinated hydrocarbon only Chlorinated hydrocarbon only (alone)
Halogenated hydrocarbon: other Other halogenated hydrocarbon
Other Other type of alcohol
Unknown Unknown type of alcohol
Unknown rubbing alcohol Rubbing alcohol: unknown
Valproic acid Valproic acid Valproic acid
APAP, acetaminophen; ASA, acetylsalicylic acid or aspirin; DXM, dextromethorphan; PPA, phenylpropanolamine; TESS, toxic exposure surveillance system.
aThese toxins were not analyzed because they did not have their own specific Major or Minor Category in the TESS database.
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to assume that many practicing nephrologists are less
comfortable and experienced with HP and opt for HD
instead.
The increased rates of HD use may also be reflective
of a number of real and confounding events. It is possible
that the severity of poisoning has increased, necessitating
more aggressive interventions. In fact, data actually
suggest increased national mortality rates from unintentional
poisoning.10 In addition, there may be trends in
pharmacotherapeutics that result in more overdoses with
drugs that are amenable to treatment with HD. The increased
utilization of valproic acid in psychiatric patients might
serve as an example of this shift. Likewise, the improved
safety and availability of HD may have resulted in an
increased use in cases that would have previously been
treated conservatively. Alternatively, it is possible that there is
a trend toward more aggressive treatment strategies by
practitioners, or an increased awareness of HD as a treatment
modality. The cost of HP cartridges is quite high in
comparison to HD membranes in the United States and this
contributes to their diminished availability;8 this may not be
an issue elsewhere in the world. Finally, it must be
acknowledged that these trends might represent reporting
biases on the behalf of treating physicians and improved
follow-up and documentation on the part of poison centers.
However, increased reporting frequency by treating physi-
cians could not account for the changes as the rates of
extracorporeal removal for HP and for some toxins have gone
down, suggesting that the data reflect true and accurate
trends. Whether such trends are occurring outside the United
States is not known.
Regardless of any of the above reasons for the increased
use of HD compared to HP, replacing HP with HD may not
be appropriate in all clinical settings. For example, Table 4
shows that HD was the only extracorporeal removal
technique performed for several patients exposed to para-
quat. Although we do not know the circumstances or the
specific reasons HD was initiated, we must stress that HP is
the modality of choice for extracorporeal removal of
paraquat and should be started as soon as possible (within
2–4 h) for maximum effectiveness.11,12 Attempts to remove
the drug later after exposure may be futile.
It is unclear what effect fomepizole has had on the use of
HD in the treatment of methanol and ethylene glycol
intoxications. Figure 4 clearly shows an increase in the use
of extracorporeal removal techniques for both of these toxins.
The decision of when and whether to use fomepizole alone,
fomepizole with HD, or HD alone can be complicated and
includes variables such as the clinical setting, acid-base status,
manifestations of toxicity, serum level of toxic alcohol, and
the availability of HD.13,14
The declining use of HP also parallels the decline in
theophylline as an indication for extracorporeal removal.
Prescriptions of this drug for asthma and chronic obstructive
pulmonary disease have declined during the study period due
to its toxicity and narrow therapeutic window.15,16 Its
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Figure 2 | Normalized number of cases receiving hemodialysis
and hemoperfusion.
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Figure 3 | Normalized number of cases receiving peritoneal
dialysis. Peritoneal dialysis was no longer recorded in TESS after
1992.
One-toxin
13,995
• HD = 12,706 
• HP = 1261 
• PD = 28 
Two-toxin
3577
• HD = 3531 
• HP = 351 
• PD = 6 
311 cases counted 2x 
Multi-toxin 
1779
• HD = 2027 
• HP = 89 
• PD = 0 
292 cases counted 2x 
18 cases counted 3x 
3 cases counted 4x 
Total number of cases receiving 
extracorporeal removal  
19,351
(1) The number of cases receiving HD, HP and PD were normalized by  
correcting for the number of exposures reported annually to TESS (see 
Figures 2 and 3).
(2) The most common toxin responsible for cases receiving HD and HP 
was totaled annually. Cases receiving PD were not included given its 
infrequent use. The most common toxins were reported in select time 
periods (see Tables 2 and 3). 
Cases with renal and miscellaneous effects ‘unrelated’ or ‘unknown if
related’ to the toxin were excluded (1993-2005).  The remaining cases 
were thought to have had extracorporeal removal for toxin removal or toxin
effect.  The number of cases receiving HD/HP was normalized to the 
annual number of calls (see Figure 4 and Table 4). 
Figure 1 | Summary of analysis of TESS data. HD, hemodialysis;
HP, charcoal hemoperfusion; PD, peritoneal dialysis.
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availability to adolescents who may be prone to using the
drugs inappropriately or in suicide gestures has declined as
well. This drug constituted one of the more frequent
indications for HP but is now reasonably well removed by
HD, which also addresses associated electrolyte abnormalities.
PD is an extracorporeal removal modality whose effec-
tiveness not only relies on dialysate flow rate, the surface area
of the peritoneum and the molecular weight of the
compound, but is also dramatically decreased in hypotensive
patients. Comparing PD and HD with regards to the half-life,
clearance rate, and drug removal of theophylline, PD
performance was much worse,17 suggesting a limited role of
PD in the overdose setting where rapid removal of toxin is
desired. The very low number of cases reported to TESS and
its eventual removal from the database in 1993 support the
hypothesis that PD is too slow to be useful and should never
be the method of choice for extracorporeal removal in the
toxic exposure setting.
The post hoc analysis of our poison center data shows that
our methods do incur a false inclusion rate of approximately
3.6% of cases and a false exclusion rate of approximately
8.6%. The net effect, if the New York data are representative
of the national TESS data, is that cases are underreported and
trends showing increases in overall numbers of procedures
and for individual toxins are real. All of these cases were
identified from their documentation, usually performed by
specialists in poison information. Checking an incorrect box
or not marking a specific box could result in the inclusion or
Table 3 | The most common toxins responsible for cases receiving hemoperfusion (total number)
1985–1990 1991–1995 1996–2000 2001–2005
Aminophylline (167) Aminophylline (162) Aminophylline (58) Carbamazepine (38)
Acetaminophen (25) Barbiturate (24) Carbamazepine (16) Lithium (30)
Barbituratea (23) Acetaminophen (12) Benzodiazepine (14) Ethylene glycol (22)
Carbamazepine (15) Carbamazepine (11) Valproic acid (13) Acetaminophen (19)
Without opioidb (11) Salicylates (8) Other (12) Valproic acid (17)
Mushroom (11) Mushroom (6) Ethylene glycol (9) SSRI (17)
Salicylates (10) Unknownc (5) SSRI (9) Phenothiazine (15)
Unknownc (9) Amitriptyline (5) Barbituratea (8) Ethanol (12)
Food poisoningd (8) Valproic acid (4) Lithium (7) Biguanide (11)
Desipramine (8) Doxepin (4) Methanol (7) Other (10)
Amitriptyline (8) Barbituratee (4) Salicylates (10)
Antiarrhythmicf (8) Antiarrhythmicf (4) Carisoprodol (10)
Bee/wasp/hornet (4)
Gastrointestinal irritant (4)
SSRI, selective serotonin reuptake inhibitor.
aLong acting.
bCombination medication including a decongestant and antihistamine with or without acetaminophen, aspirin and phenylpropanaolamine.
cUnknown substance, unlikely to be a drug.
dBacterial food poisoning: unknown type.
eShort and intermediate acting.
fOther antiarrhythmic: quinidine, bretylium, procainamide, etc.
Table 2 | The most common toxins responsible for cases receiving hemodialysis (total number)
1985–1990 1991–1995 1996–2000 2001–2005
Lithium (397) Lithium (714) Lithium (1178) Lithium (2583)
Ethylene glycol (290) Ethylene glycol (649) Ethylene glycol (1138) Ethylene glycol (2077)
Methanol (236) Salicylates (358) Salicylates (580) Salicylates (1490)
Salicylates (233) Aminophylline (284) Methanol (289) Valproic acid (516)
Aminophylline (229) Methanol (240) Aminophylline (240) Acetaminophen (474)
Phenothiazine (73) Acetaminophen (135) Acetaminophen (192) Methanol (463)
Ethanol (73) Ethanol (84) Valproic acid (170) Ethanol (297)
Acetaminophen (71) Phenothiazine (65) Ethanol (111) Benzodiazepine (281)
Isopropanol (49) Isopropanol (59) Other (90) Other (274)
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Figure 4 | Trends for the most commonly accepted indications
for hemodialysis and/or hemoperfusion.
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exclusion of cases; however, it would be unlikely for this to
influence the trend in the data.
In addition to potential reporting biases discussed above,
it is essential to note that the TESS database does not contain
a specific field that allows for qualitative or quantitative
confirmation of the reported toxin, such as a serum level.
This information is typically located in the free text fields,
which are not stored on the national level and therefore not
available for routine analysis. However, we assume that these
exposures are indeed intoxications for several reasons. First,
these patients are receiving an extracorporeal removal
therapy which is a complex process involving a nephrology
consult, the placement of a large-bore intravenous catheter,
and usually an extracorporeal removal team or center.
Second, although the overall database is comprised largely
of self-reported calls from home, these cases are unique in
that the information is usually provided by medical
personnel calling from a health care facility to request
assistance in managing an ill patient.
We assumed if a case was exposed to a toxin with common
indications for extracorporeal removal (listed in Table 1) and
received HD, HP, or PD, then they received this therapy for
that toxin. One can create scenarios that can explain why this
may not be the case. For example, a patient who experiences
hypotension caused by a calcium channel blocker overdose
may develop renal failure requiring HD; however, if this
patient was also on carbamazepine, we would have classified
this case as HD for carbamazepine. Although our post hoc
analysis did show a false inclusion rate of 3.6%, our false
exclusion rate was higher at 8.6%.
Finally, continuous renal replacement therapy has been
used increasingly for toxin removal, as this may be the only
extracorporeal removal technique practical for hemodyna-
mically unstable patients.11,18,19 However, there are currently
no data fields in TESS to allow trends to be tracked. As the
efficacy and effectiveness of these continuous modalities in
the treatment of the poisoned patient remains unproven,19
the accumulation of data regarding the current utilization
patterns of these techniques would be worth accomplishing
in future TESS efforts.
Our data suggest that acetaminophen is increasingly
reported as a toxin leading to use of extracorporeal removal.
Although acetaminophen is amenable to extracorporeal
removal, HD is rarely if ever indicated. Virtually all patients
present after peak plasma concentration is achieved, N-
acetylcysteine is an antidote with documented efficacy, and
Table 4 | Number of cases receiving hemodialysis and/or hemoperfusion normalized per million calls reported to TESS
Exposure Therapy 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 2003 2004 2005
Carbamazepine Total 5.1 3.1 1.5 7.4 4.1 4.5 5.9 6.5 4.0 6.3 4.2 6.2 5.0
HD 3.4 0.5 0.5 5.1 0.9 2.7 4.1 4.2 2.6 5.9 2.9 4.5 4.5
HP 1.7 2.6 1.0 2.8 3.2 1.8 1.8 2.8 1.3 1.3 1.7 1.6 0.8
Carisoprodol Total 0.6 0.0 1.0 0.9 0.5 3.6 1.4 3.2 2.6 4.6 4.6 4.5 3.3
HD 0.6 0.0 1.0 0.9 0.5 3.6 1.4 3.2 2.2 4.2 4.6 4.5 3.3
HP 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.4 0.0 0.0 0.0
Chloral hydrate Total 1.7 2.1 2.5 0.9 0.5 0.0 1.4 0.0 0.9 0.8 0.0 0.0 1.2
HD 1.1 2.1 2.5 0.9 0.5 0.0 1.4 0.0 0.9 0.8 0.0 0.0 1.2
HP 0.6 0.0 0.5 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0
Ethchlorvynol Total 1.1 0.5 0.5 0.0 0.9 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
HD 0.6 0.5 0.5 0.0 0.9 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
HP 1.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.0 0.0
Meprobamate Total 1.7 1.6 0.5 1.4 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.4 0.0
HD 1.1 1.6 0.5 1.4 0.0 0.0 0.0 0.0 0.4 0.0 0.4 0.4 0.0
HP 0.6 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Mushroom Total 1.7 0.0 0.5 0.5 1.8 1.3 0.9 0.9 1.3 1.7 0.8 0.4 0.4
HD 1.1 0.0 0.5 0.5 1.8 1.3 0.9 0.9 0.0 1.3 0.8 0.4 0.4
HP 0.6 0.0 0.0 0.0 0.5 0.0 0.0 0.0 1.3 0.8 0.0 0.0 0.0
Paraquat Total 2.3 0.5 0.0 1.4 0.0 0.0 0.9 0.5 0.9 0.8 0.8 0.0 0.8
HD 1.7 0.0 0.0 1.4 0.0 0.0 0.5 0.5 0.9 0.8 0.8 0.0 0.8
HP 0.6 0.5 0.0 0.5 0.0 0.0 0.5 0.0 0.4 0.0 0.0 0.0 0.0
Phenytoin Total 2.9 2.1 3.0 1.9 2.7 2.2 2.3 5.1 0.9 1.7 1.7 2.1 1.7
HD 2.9 1.0 2.5 1.9 2.7 1.8 1.4 5.1 0.9 1.7 1.7 1.6 1.2
HP 0.6 1.0 0.5 0.0 0.0 0.4 0.9 0.0 0.0 0.0 0.0 0.4 0.4
Valproic acid Total 2.9 5.2 5.4 9.7 14.1 16.1 22.7 23.5 25.1 24.4 21.7 21.3 20.6
HD 1.1 5.2 4.4 8.8 12.8 14.7 20.9 22.6 24.7 24.4 20.9 21.3 20.6
HP 1.7 0.5 1.0 0.9 1.8 2.2 2.3 0.9 0.4 0.0 1.3 0.4 0.4
HD, hemodialysis; HP, charcoal hemoperfusion.
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extracorporeal removal has never been demonstrated to alter
outcome in this setting. The explanation for increasing use of
HD in our data requires further investigation.
In conclusion, among cases with toxic exposures reported
to United States poison centers between the years 1985 and
2005, the use of HD has increased and the use of HP has
decreased. PD was never commonly reported, generally has
no accepted indications in poisoning, and is no longer
recorded in TESS. Ethylene glycol and lithium were the most
common toxins responsible for HD during this time period,
and HD as a treatment modality for these exposures
continues to increase in frequency. Theophylline, once a
common potential toxin leading to HD and/or HP, has
decreased dramatically as an indication. The profile of toxins
responsible for HD and HP appears to be changing with, for
example, increased reports of acetaminophen and valproic
acid exposures, which requires further evaluation.
MATERIALS AND METHODS
Data were accessed for all cases recorded electronically in the TESS
database from 1985 to 2005 where therapeutic options for HD, HP,
or PD were not null. This approach yielded four different types of
cases where extracorporeal removal was (1) performed, (2)
recommended and performed, (3) recommended but not per-
formed, and (4) recommended, but unknown if performed. Data
were entered into a Microsoft Access database, from which queries
were built and tallied.
Cases were initially divided into one-toxin exposures, two-toxin
exposures, and multi-toxin (three or more) exposures. Only cases in
which extracorporeal removal was known to have been performed
were used for further analysis. Each toxin exposure recorded in TESS
contains two headings: Major Category and Minor Category. The
Major Category is either a common toxin (for example, methanol),
a class of toxin (for example, benzodiazepine), or a toxin description
(for example, adult formulation), whereas the Minor Category
either mirrors the Major Category, further classifies the Major
Category (for example, automotive product), or specifies the Major
Category (for example, aspirin: adult formulation).
A list of toxins that have generally accepted indications for
extracorporeal removal in overdose was adopted from a standard
reference1 and is presented along with the corresponding descriptors
from TESS in Table 1. As illustrated in the table, some toxins did not
have specific entries in the TESS database and thus could not be
analyzed. These included aminoglycosides, atenolol, disopyramide,
methotrexate, phenobarbital, and trichlorethanol. In addition, even
though ethanol is amenable to extracorporeal removal, it was not
included in Table 1 because the clinical circumstances in which
ethanol removal is appropriate are extremely rare, it is a very
common co-ingestion in an intentional overdose, and it is also used
as a therapy for toxic alcohol ingestion.
For the purposes of this study, cases with exposures to any of the
toxins listed in Table 1 that had extracorporeal removal performed
were assumed to have received that therapy for that particular toxin.
Cases with exposures to combination products that contained a
toxin listed in Table 1 were assumed to have extracorporeal removal
for the listed toxin; for example, if the exposure was a combination
of an opioid and aspirin, then it was assumed extracorporeal
removal was performed for salicylate removal. However, if a
combination product contained two toxins listed in Table 1 (for
example, ‘aspirin with carisoprodol’), then this product remained as
its own individual category and was not counted separately for each
toxin. Thus, cases exposed to two or more different toxins in Table 1
were counted twice or more, one for each toxin; the total number of
these cases was reported. Cases with exposure to the same toxin in
two different preparations were only counted once; for example,
exposure to ‘aspirin’ and ‘aspirin with oxycodone’ would be counted
once for salicylates.
Using this methodology, the most common toxins responsible
for cases receiving HD and HP were totaled annually and reported
as total number of procedures performed. To correct for potential
biases introduced by annual variations in the size of the database
(resulting from reporting trends and changes in the number of
participating poison centers) these cases were normalized using the
total number of exposures reported in each published annual TESS
report. To help identify possible trends, the annual results were then
grouped according to the following time periods: 1985–1990,
1991–1995, 1996–2000, and 2001–2005. Further analysis of PD
therapy was not performed, as this therapy was not recorded in
TESS after 1992.
Selected toxins listed in Table 1 were examined for trends in the
use of HD and HP. These included aminophylline and theophylline,
antiepileptics (for example, carbamazepine, phenytoin, valproic
acid), ethylene glycol, lithium, methanol, mushrooms, paraquat,
salicylates, and sedative hypnotics (for example, carisoprodol,
chloral hydrate, ethchlorvynol, meprobamate). Initially, as described
above, only those cases that had HD or HP either ‘performed’ or
‘recommended and performed’ were included. Next, the Clinical
Effects major field for these cases was analyzed. Cases with renal
effects (for example, creatinine, hemo/myoglobinuria, oliguria/
anuria, renal failure) or miscellaneous effects (for example, creatine
phosphokinase elevated, electrolyte abnormality, rhabdomyolysis)
marked ‘unrelated’ or ‘unknown if related’ to the toxin were
excluded from further analysis to prevent inclusion of cases where
the toxin was present, but an extracorporeal removal technique was
performed for commonly accepted medical reasons. As the ability to
document if clinical effects were ‘related’, ‘unrelated’, or ‘unknown if
related’ was introduced in the database in 1993, this analysis
includes data only from 1993 to 2005. Again, as previously
described, these cases were then normalized to the annual number
of calls received by poison centers.
In an attempt to understand the limitations of this database we
undertook a post hoc analysis of our own poison center’s data. Our
poison center is one of the oldest continually operated centers in the
USA and receives between 40,000 and 50,000 exposures each year,
representing approximately 2% of the national database. Because we
have the complete records (including the free text areas) we were
specifically able to address many of the potential limitations (for
example, inability of TESS to record serum levels of particular
toxins). Searchable computerized data exist at our center from 1
January 2000 forward. The complete electronic record of all cases
receiving HD and/or HP from 2000 to 2005 were retrieved and
printed from the database. All cases were sorted by two of the
authors (WH and RH) as described in the methodology above.
Those cases with an exposure to toxins listed in Table 1 were given to
two medical toxicology fellows employed at the poison center who
were unaware of the present paper. For each case they were asked
one question: do the free text notes contradict that extracorporeal
removal was performed for the toxin-related issue? When they
disagreed, a third fellow was used to adjudicate the results. The
number of these cases would give an indication of a false inclusion
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rate. In addition, in an attempt to ascertain a false exclusion rate, the
two authors (WH and RH) reviewed these cases again selecting
those that would have been excluded for having unrelated medical
indications for HD, as described in the methodology above. Cases
with evidence in the free text to suggest that extracorporeal removal
was indeed performed for a toxin-related issue were totaled and a
false exclusion rate was calculated.
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